Plant · Scientific monograph
Astragalus propinquus
Astragalus / Huang Qi / Milk-vetch root
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Immunological Research, Stress Response Research, Cardiovascular System, Cellular Ageing Research
Research overview
Historical use
Astragalus (Huang Qi) has occupied a central position in Traditional Chinese Medicine for over 2,000 years, classified as a superior tonic herb in the Shen Nong Ben Cao Jing (c. 100 CE). Used to tonify the 'wei qi' (defensive energy), treat chronic fatigue, spontaneous sweating, prolapsed organs, and poor wound healing. It remains one of the most widely used herbs in Chinese herbal formulae and is a principal ingredient in Fu Zheng therapy — the TCM approach to immune restoration in oncology patients.
Modern research context
Astragalus root extracts demonstrate immunomodulatory, anti-fibrotic, cardioprotective, and anti-ageing properties. Astragaloside IV (ASIV) is extensively investigated for non-alcoholic fatty liver disease (NAFLD) via modulation of insulin resistance, lipid metabolism, and oxidative stress [2]. Detailed pharmacokinetic mapping in rat plasma identified 127 distinct in vivo existence forms of Astragali Radix components by UHPLC-Q-TOF-MS/MS [4]. Astragalus polysaccharides (APS) enhance amino acid absorption in older adults [3], and polysaccharide nanoparticles improve bioavailability of co-administered phytochemicals [8]. Cycloastragenol, generated from ASIV by gut microbial biotransformation, activates telomerase and is investigated for anti-ageing applications [1]. CYP450 and P-gp modulation by Astragali Radix creates clinically relevant herb-drug interaction potential [5].
Adverse effects
Generally well-tolerated at standard doses (9–30 g crude root equivalent). Rare GI upset, bloating, and mild diuresis. Theoretical immunostimulatory activity may worsen autoimmune conditions or interact with immunosuppressive therapy. High-dose or prolonged use may dysregulate immune homeostasis.
Contraindications
Caution with immunosuppressants (cyclosporine, tacrolimus) due to opposing immunostimulatory activity. CYP2C9/CYP3A4 modulation raises concern with warfarin, cyclosporine, and statins [5]. Avoid in acute infections (risk of cytokine surge). Insufficient safety data in pregnancy; avoid medicinal doses.
Clinical and phytochemical data
Used part
Dried root (Radix Astragali / Huang Qi)
Primary active compounds
Astragaloside IV (cycloartane saponin)
Astragaloside I, II, III
Astragalus polysaccharides (APS)
Cycloastragenol (aglycone metabolite)
Calycosin (isoflavone)
Formononetin (isoflavone)
Astragalin (flavonol glycoside)
Mechanism of action
Immunomodulation via TLR4/NF-κB activation by astragalus polysaccharides, stimulating macrophage and NK-cell activity [2]. ASIV exerts anti-fibrotic effects through TGF-β1/Smad pathway suppression and AMPK-dependent lipid metabolism regulation in hepatocytes [2]. Cycloastragenol activates telomerase reverse transcriptase (TERT), extending telomere length in senescent immune cells [1]. Flavonoids (calycosin, formononetin) act as phytoestrogens via ERα/ERβ agonism and modulate PI3K/Akt and MAPK survival pathways [5]. Saponin fractions improve intestinal amino acid absorption through gut microbiome modulation [3, 8].
Pharmacokinetics
Absorption
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — UHPLC-Q-TOF-MS/MS mapping of rat plasma following oral administration identified 127 distinct in vivo existence forms of Astragali Radix components, including parent saponins, metabolites, and protein-bound adducts (Xiang LH et al., 2025) [4]. Astragaloside IV has poor oral bioavailability in rodents (<5%); partial conversion to the more bioavailable cycloastragenol occurs via gut microbial deglycosylation [1]. Flavonoids calycosin and formononetin show moderate absorption; pharmacokinetic parameters (t½, Cmax, AUC) characterised in rat plasma by UHPLC-MS/MS (Du R et al., 2024) [6].
Distribution
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — ASIV distributes to liver, kidney, and lung in rodent models following oral dosing; tissue concentrations peak at 1–2 hours post-administration [2]. Flavonoids exhibit moderate plasma protein binding and distribute to peripheral tissues including bone and cardiovascular tissue [6].
Metabolism
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Astragalosides undergo stepwise deglycosylation by intestinal and hepatic β-glucosidases and gut microbiota, generating cycloastragenol as the principal active metabolite [1]. Flavonoids (calycosin, formononetin) are substrates of CYP3A4 and undergo O-methylation; phase II glucuronidation and sulfation are the principal conjugation pathways [5, 6]. Astragali Radix modulates CYP2C9, CYP3A4, UGT1A6, and P-glycoprotein activity [5].
Excretion
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Saponin conjugates are primarily eliminated via biliary excretion; flavonoid glucuronides and sulfates are recovered in urine. Polysaccharide fractions are degraded by colonic microbiota with minimal systemic absorption [6, 8].
Safety and interactions
Drug interactions
Astragali Radix has documented herb-drug interaction potential from a metabolic perspective. Wang T et al. (2025) demonstrated modulation of CYP2C9, CYP3A4, UGT1A6, and P-glycoprotein (P-gp) activity in metabolic assays [5]. CYP2C9 modulation may alter plasma concentrations of warfarin, phenytoin, and NSAIDs; CYP3A4 interactions may affect cyclosporine, tacrolimus, statins, and macrolide antibiotics. P-gp inhibition may increase bioavailability of transported drugs (digoxin, dabigatran) [5]. Formal clinical pharmacokinetic interaction studies are not yet available; clinical significance of these interactions remains to be quantified in human trials.
Toxicity
Acute oral toxicity is low; LD50 for standardised Astragalus extracts exceeds 100 g/kg in rodents. Chronic use in clinical settings is generally well-tolerated without significant hepatic or haematological adverse effects [3].
Special precautions
Pregnancy
Insufficient human safety data. High-dose medicinal preparations not recommended. Low-dose dietary use likely low-risk; controlled data absent.
Lactation
Excretion in breast milk not studied. Medicinal-dose preparations should be avoided.
Hepatic impairment
ASIV is under active investigation for NAFLD treatment [2]; use with caution in severe hepatic impairment due to altered first-pass metabolism and potential metabolite accumulation.
Renal impairment
Limited data. Standard precautions apply; dose reduction may be appropriate in severe renal impairment.
Sources and references
- [1] - Jiang H et al., "Discrimination of the significance of astragalosides in Astragalus radix based on in vivo exposure levels.", Journal of Ethnopharmacology, 2026, PMID: 41734824
- [2] - Wang H et al., "Recent advances in the treatment of non-alcoholic fatty liver disease with astragaloside IV.", Acta Pharmaceutica, 2025, PMID: 40668649
- [3] - Zhuang SR et al., "Effects of Astragalus membranaceus and Panax notoginseng Saponins Extract on Pharmacokinetics of whey protein components in older adults.", Nutrients, 2026, PMID: 41683325
- [4] - Xiang LH et al., "Phenomenological pharmacokinetics of traditional Chinese medicines: A proof-of-concept study with Astragali Radix.", Journal of Ethnopharmacology, 2025, PMID: 40287114
- [5] - Wang T et al., "Herb-drug interaction potential of Astragali Radix: a metabolic perspective.", Drug Metabolism Reviews, 2025, PMID: 39692050
- [6] - Du R et al., "Pharmacokinetics of two triterpenoid saponins and three flavonoids in Astragalus membranaceus leaves in rats.", Journal of Pharmaceutical and Biomedical Analysis, 2024, PMID: 39154580
- [7] - Duan Y et al., "A comprehensive pharmacokinetic strategy for systematic evaluation of whole interaction of Astragalus-Fructus Corni compatibility.", Journal of Ethnopharmacology, 2025, PMID: 39603397
- [8] - Zhang Y et al., "The synergistic effect of Huangqi Gegen decoction on thrombosis relates to astragalus polysaccharide-improved oral delivery.", Journal of Ethnopharmacology, 2024, PMID: 39053719